Skip to main content
INDV
NASDAQ Life Sciences

Indivior Q3: Revenue Up 13% to $356M, Net Income $137M Ahead of Nov 2 Supernus Close

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$36.51
Mkt Cap
$4.104B
52W Low
$24.28
52W High
$42.81
52W Position info
50% above low
Off High info
15% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

INDV sits 50% above its 52-week low of $24.28.

Summary

Indivior reported Q3 2026 revenue of $356 million (+13%) and net income of $137 million, with SUBLOCADE up 22% to $267 million and gross margin at 86%. The filing also discloses a $95 million SUBUTEX France/Germany divestiture and confirms the Supernus merger is expected to close on or about November 2, 2026.


Key Events · Earnings and Guidance · INDV

  • Q3 Revenue $356M, Up 13%

    Net revenue rose to $356 million from $314 million, with U.S. revenue up 15% to $307 million and SUBLOCADE up 24% to $252 million in the U.S.

  • Net Income $137M, EPS $1.12

    Gross margin expanded to 86% from 73% and R&D fell 84% to $5 million after pipeline cessation, driving diluted EPS of $1.12 versus $0.33 a year ago.

  • Convertible Notes Moved to Current

    The $488 million carrying value of the 0.625% Convertible Senior Notes due 2031 is classified as current because the Special Dividend gave holders a temporary conversion right; it reverts to noncurrent after the October 30 record date.

  • $95M SUBUTEX Divestiture Signed

    On October 19, 2026 Indivior agreed to sell its SUBUTEX tablet business in France and Germany for $95 million, with 90% paid at closing; the business was under 4% of 2025 net revenue.


Analysis · INDV · Life Sciences

The SUBLOCADE engine is still compounding: total SUBLOCADE revenue rose 22% to $267 million and gross margin jumped to 86% from 73%, while costs collapsed as the company wound down pipeline spending. That combination produced $137 million of quarterly net income versus $42 million a year ago. The balance sheet carries $305 million of cash and $317 million of nine-month operating cash flow, but the $488 million convertible notes now sit in current liabilities because the $8.13 special dividend triggered a temporary conversion right; that classification reverts to noncurrent after the October 30 record date. With the Supernus merger closing on or about November 2, 2026, this is effectively the last standalone quarter. The only new strategic item is the $95 million SUBUTEX France/Germany divestiture signed October 19, and the dental-injury MDL (about 22,098 plaintiffs) remains unquantified.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INDV was trading at $36.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $24.28 to $42.81. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INDV - Latest Insights

INDV
Nov 02, 2026, 9:27 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $35.56
Real-time Price: $36.41 info
Change: +$0.850 (+2%) info
Market Cap: $4.282B info
INDV
Oct 29, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $35.25
Real-time Price: $36.41 info
Change: +$1.16 (+3%) info
Market Cap: $4.282B info
INDV
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.44
Real-time Price: $36.41 info
Change: +$1.97 (+6%) info
Market Cap: $4.282B info
INDV
Oct 29, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $34.44
Real-time Price: $36.41 info
Change: +$1.97 (+6%) info
Market Cap: $4.282B info
INDV
Oct 06, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.99
Real-time Price: $36.41 info
Change: +$0.420 (+1%) info
Market Cap: $4.282B info